317 related articles for article (PubMed ID: 31075690)
1. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
[TBL] [Abstract][Full Text] [Related]
2. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
[TBL] [Abstract][Full Text] [Related]
3. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
[TBL] [Abstract][Full Text] [Related]
4. Generation of a patient-specific induced pluripotent stem cell line, KSCBi006-A, for osteogenesis imperfecta type I with the COL1A1, c.3162delT mutation.
Kim BY; Ko JM; Park MH; Koo SK
Stem Cell Res; 2019 Dec; 41():101622. PubMed ID: 31715426
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 correction of a dominant cis-double-variant in COL1A1 isolated from a patient with osteogenesis imperfecta increases the osteogenic capacity of induced pluripotent stem cells.
Cao Y; Li L; Ren X; Mao B; Yang Y; Mi H; Guan Y; Li S; Zhou S; Guan X; Yang T; Zhao X
J Bone Miner Res; 2023 May; 38(5):719-732. PubMed ID: 36734182
[TBL] [Abstract][Full Text] [Related]
6. Identification of a family with van der Hoeve's syndrome harboring a novel COL1A1 mutation and generation of patient-derived iPSC lines and CRISPR/Cas9-corrected isogenic iPSCs.
Li S; Mei L; He C; Cai X; Wu H; Wu X; Liu Y; Feng Y; Song J
Hum Cell; 2024 May; 37(3):817-831. PubMed ID: 38379122
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
[TBL] [Abstract][Full Text] [Related]
8. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
Lilianty J; Bateman JF; Lamandé SR
Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
[TBL] [Abstract][Full Text] [Related]
9. Generation of a SOX9-tdTomato reporter human iPSC line, MCRIi001-A-2, using CRISPR/Cas9 editing.
Nur Patria Y; Lilianty J; Elefanty AG; Stanley EG; Labonne T; Bateman JF; Lamandé SR
Stem Cell Res; 2020 Jan; 42():101689. PubMed ID: 31884373
[TBL] [Abstract][Full Text] [Related]
10. Using CRISPR/Cas9 to generate a heterozygous COL2A1 p.R719C iPSC line (MCRIi019-A-6) model of human precocious osteoarthritis.
Yammine KM; Mirda Abularach S; Sampurno L; Bateman JF; Lamandé SR; Shoulders MD
Stem Cell Res; 2023 Mar; 67():103020. PubMed ID: 36682125
[TBL] [Abstract][Full Text] [Related]
11. An integration-free iPSC line (SDQLCHi013-A) derived from a patient with maple syrup urine disease carrying compound heterozygote mutations in BCKDHA gene.
Zhang H; Ma Y; Li X; Yang X; Li Y; Guan J; Dong R; Gai Z; Liu Y
Stem Cell Res; 2019 Dec; 41():101585. PubMed ID: 31775088
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
[TBL] [Abstract][Full Text] [Related]
13. Generation of four patient-specific pluripotent induced stem cell lines from two Brazilian patients with amyotrophic lateral sclerosis and two healthy subjects.
Gubert F; Vasques JF; Cozendey TD; Domizi P; Toledo MF; Kasai-Brunswick TH; Loureiro MPS; Lima JMB; Gress CH; Cabello GMK; Cabello PH; Borgonovo T; Vaz IM; Silva R; Mendez-Otero R
Stem Cell Res; 2019 May; 37():101448. PubMed ID: 31077962
[TBL] [Abstract][Full Text] [Related]
14. Genotypic Characterization of a Chinese Family with Osteogenesis Imperfecta and Generation of Disease-Specific Induced Pluripotent Stem Cells.
Li D; Ou M; Dai G; Zhu P; Luo Q; Chen J; Shah Z; Samokhvalov IM; Yin L; Sun G; Tang D; Dai Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):336. PubMed ID: 38179771
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B.
Hansen M; Varga E; Wüst T; Mellink C; van der Kevie-Kersemaekers AM; Marneth AE; von Lindern M; van der Reijden B; van den Akker E
Stem Cell Res; 2017 Dec; 25():34-37. PubMed ID: 29055225
[TBL] [Abstract][Full Text] [Related]
16. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
[TBL] [Abstract][Full Text] [Related]
18. Generation of a heterozygous TPM1-E192K knock-in human induced pluripotent stem cell line using CRISPR/Cas9 system.
Kang JY; Mun D; Chun Y; Kim H; Yun N; Lee SH; Joung B
Stem Cell Res; 2022 Aug; 63():102878. PubMed ID: 35917600
[TBL] [Abstract][Full Text] [Related]
19. Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides.
Dong Y; Peng T; Wu W; Tan D; Liu X; Xie D
J Int Med Res; 2019 Apr; 47(4):1717-1730. PubMed ID: 30819013
[TBL] [Abstract][Full Text] [Related]
20. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
